 | • レポートコード：MRC2304J0008 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、247ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の当市場調査レポートでは、世界のGLP-1受容体作動薬市場規模が、2021年3,632.28百万ドルから2022年4,016.94百万ドルへと成長し、更に年平均10.84％増大して2027年までに6,737.14百万ドルに達すると予測しています。当書は、GLP-1受容体作動薬の世界市場を総合的に分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、製品別（ビデュリオン、オゼンピック、サクセンダ、トルリシティ、ビクトーザ）分析、薬剤分類別（アルビグルチド、デュラグルチド、エクセナチド、リラグルチド、リキシセナチド）分析、投与経路別（経口、非経口）分析、用途別（肝硬変、非アルコール性脂肪性肝炎、肥満、2型糖尿病）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの項目をまとめています。なお、当書に掲載されている企業情報には、9 Meters Biopharma, Inc.、A-S Medication Solutions, LLC、Amgen Inc.、AstraZeneca PLC、Eli Lilly and Company、Hanmi Pharmaceutical co., ltd.、Innovent Biologics, Inc.、Intarcia Therapeutics, Inc.、Jiangsu Hengrui Medicine Co., Ltdなどが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界のGLP-1受容体作動薬市場規模：製品別 - ビデュリオンの市場規模 - オゼンピックの市場規模 - サクセンダの市場規模 - トルリシティの市場規模 - ビクトーザの市場規模 ・世界のGLP-1受容体作動薬市場規模：薬剤分類別 - アルビグルチドの市場規模 - デュラグルチドの市場規模 - エクセナチドの市場規模 - リラグルチドの市場規模 - リキシセナチドの市場規模 ・世界のGLP-1受容体作動薬市場規模：投与経路別 - 経口薬の市場規模 - 非経口薬の市場規模 ・世界のGLP-1受容体作動薬市場規模：用途別 - 肝硬変における市場規模 - 非アルコール性脂肪性肝炎における市場規模 - 肥満における市場規模 - 2型糖尿病における市場規模 ・世界のGLP-1受容体作動薬市場規模：地域別 - 南北アメリカのGLP-1受容体作動薬市場規模 アメリカのGLP-1受容体作動薬市場規模 カナダのGLP-1受容体作動薬市場規模 ブラジルのGLP-1受容体作動薬市場規模 ... - アジア太平洋のGLP-1受容体作動薬市場規模 日本のGLP-1受容体作動薬市場規模 中国のGLP-1受容体作動薬市場規模 インドのGLP-1受容体作動薬市場規模 韓国のGLP-1受容体作動薬市場規模 台湾のGLP-1受容体作動薬市場規模 ... - ヨーロッパ/中東/アフリカのGLP-1受容体作動薬市場規模 イギリスのGLP-1受容体作動薬市場規模 ドイツのGLP-1受容体作動薬市場規模 フランスのGLP-1受容体作動薬市場規模 ロシアのGLP-1受容体作動薬市場規模 ... - その他地域のGLP-1受容体作動薬市場規模 ・競争状況 ・企業情報 |
The Global GLP-1 Receptor Agonist Market size was estimated at USD 3,632.28 million in 2021 and expected to reach USD 4,016.94 million in 2022, and is projected to grow at a CAGR 10.84% to reach USD 6,737.14 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the GLP-1 Receptor Agonist to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Product, the market was studied across Bydureon, Ozempic, Saxenda, Trulicity, and Victoza.
Based on Drug Class, the market was studied across Albiglutide, Dulaglutide, Exenatide, Liraglutide, Lixisenatide, and Semaglutide.
Based on Route of Administration, the market was studied across Oral and Parenteral.
Based on Application, the market was studied across Liver Cirrhosis, Non-alcoholic Steatohepatitis, Obesity, and Type 2 Diabetes Mellitus.
Based on Distribution Channel, the market was studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for GLP-1 Receptor Agonist market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the GLP-1 Receptor Agonist Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global GLP-1 Receptor Agonist Market, including 9 Meters Biopharma, Inc., A-S Medication Solutions, LLC, Amgen Inc., AstraZeneca PLC, Eli Lilly and Company, Hanmi Pharmaceutical co., ltd., Innovent Biologics, Inc., Intarcia Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Ltd, Novo Nordisk A/S, Optum, Inc., PegBio Co., Ltd., Pfizer Inc., Sanofi S.A., and Sun Pharmaceutical Industries Limited.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global GLP-1 Receptor Agonist Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global GLP-1 Receptor Agonist Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global GLP-1 Receptor Agonist Market?
4. What is the competitive strategic window for opportunities in the Global GLP-1 Receptor Agonist Market?
5. What are the technology trends and regulatory frameworks in the Global GLP-1 Receptor Agonist Market?
6. What is the market share of the leading vendors in the Global GLP-1 Receptor Agonist Market?
7. What modes and strategic moves are considered suitable for entering the Global GLP-1 Receptor Agonist Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence rate of lifestyle diseases such as obesity, atherosclerosis, and cardiovascular diseases
5.1.1.2. Increase in the number of diabetic patients and recent advancement in the treatment of Type 2 Diabetes Mellitus
5.1.1.3. Growing number of approval for novel products
5.1.2. Restraints
5.1.2.1. Patent expiry of GLP-1 receptor agonist drugs
5.1.3. Opportunities
5.1.3.1. Rising new product launched and ongoing development of strong product pipeline
5.1.3.2. Developing focus on the collaboration activities to obtain commercialization rights
5.1.4. Challenges
5.1.4.1. Severe risks and limitations such as renal impairment, pancreatitis, diabetic ketoacidosis
5.2. Cumulative Impact of COVID-19
6. GLP-1 Receptor Agonist Market, by Product
6.1. Introduction
6.2. Bydureon
6.3. Ozempic
6.4. Saxenda
6.5. Trulicity
6.6. Victoza
7. GLP-1 Receptor Agonist Market, by Drug Class
7.1. Introduction
7.2. Albiglutide
7.3. Dulaglutide
7.4. Exenatide
7.5. Liraglutide
7.6. Lixisenatide
7.7. Semaglutide
8. GLP-1 Receptor Agonist Market, by Route of Administration
8.1. Introduction
8.2. Oral
8.3. Parenteral
9. GLP-1 Receptor Agonist Market, by Application
9.1. Introduction
9.2. Liver Cirrhosis
9.3. Non-alcoholic Steatohepatitis
9.4. Obesity
9.5. Type 2 Diabetes Mellitus
10. GLP-1 Receptor Agonist Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. Americas GLP-1 Receptor Agonist Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific GLP-1 Receptor Agonist Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa GLP-1 Receptor Agonist Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.1.1. Quadrants
14.1.2. Business Strategy
14.1.3. Product Satisfaction
14.2. Market Ranking Analysis, By Key Player
14.3. Market Share Analysis, By Key Player
14.4. Competitive Scenario
14.4.1. Merger & Acquisition
14.4.2. Agreement, Collaboration, & Partnership
14.4.3. New Product Launch & Enhancement
14.4.4. Investment & Funding
14.4.5. Award, Recognition, & Expansion
15. Company Usability Profiles
15.1. 9 Meters Biopharma, Inc.
15.1.1. Business Overview
15.1.2. Key Executives
15.1.3. Product & Services
15.2. A-S Medication Solutions, LLC
15.2.1. Business Overview
15.2.2. Key Executives
15.2.3. Product & Services
15.3. Amgen Inc.
15.3.1. Business Overview
15.3.2. Key Executives
15.3.3. Product & Services
15.4. AstraZeneca PLC
15.4.1. Business Overview
15.4.2. Key Executives
15.4.3. Product & Services
15.5. Eli Lilly and Company
15.5.1. Business Overview
15.5.2. Key Executives
15.5.3. Product & Services
15.6. Hanmi Pharmaceutical co., ltd.
15.6.1. Business Overview
15.6.2. Key Executives
15.6.3. Product & Services
15.7. Innovent Biologics, Inc.
15.7.1. Business Overview
15.7.2. Key Executives
15.7.3. Product & Services
15.8. Intarcia Therapeutics, Inc.
15.8.1. Business Overview
15.8.2. Key Executives
15.8.3. Product & Services
15.9. Jiangsu Hengrui Medicine Co., Ltd
15.9.1. Business Overview
15.9.2. Key Executives
15.9.3. Product & Services
15.10. Novo Nordisk A/S
15.10.1. Business Overview
15.10.2. Key Executives
15.10.3. Product & Services
15.11. Optum, Inc.
15.11.1. Business Overview
15.11.2. Key Executives
15.11.3. Product & Services
15.12. PegBio Co., Ltd.
15.12.1. Business Overview
15.12.2. Key Executives
15.12.3. Product & Services
15.13. Pfizer Inc.
15.13.1. Business Overview
15.13.2. Key Executives
15.13.3. Product & Services
15.14. Sanofi S.A.
15.14.1. Business Overview
15.14.2. Key Executives
15.14.3. Product & Services
15.15. Sun Pharmaceutical Industries Limited
15.15.1. Business Overview
15.15.2. Key Executives
15.15.3. Product & Services
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing